- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06093815
Étude prospective pour évaluer les réponses tissulaires après injection de produits biostimulateurs
Étude comparative prospective, contrôlée et sur un seul site pour identifier et évaluer les réponses tissulaires après injection de divers produits biostimulateurs
The objective of this study is to identify and assess in vivo tissue responses after injection with various biostimulatory products at various timepoints. The study will also provide tissue specimens which will be used in a subsequent study.
Safety endpoint: incidence of adverse events.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The objective of this study is to identify and assess tissue responses after injection with various biostimulatory products that are already used in the market and have CE approval. The study will assess in vivo tissue responses and provide tissue specimens which will be used in a subsequent study, under a separate protocol.
Assessments under this protocol will include ultrasound of in vivo tissue.
Safety endpoint: incidence of adverse events.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Marbella, Espagne
- Ocean Clinic - Av. Ramon y Cajal 7, 29601
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Healthy male & females; 22 to 65 years of age.
- Voluntary participation
- Ability to comprehend and provide informed consent.
- Participants agree NOT to use any topical agents or products that will induce skin peeling or change the appearance of the skin in the treatment area, during the study period.
- Participants agree NOT to undergo any aesthetic treatments that influence the appearance of the skin in the treatment area during the study period.
- Participants agree NOT to undergo any surgical treatments in the treatment area during the study period.
- Participants agree NOT to take part in another clinical study or undergo other treatments during the study period.
Exclusion Criteria:
- Any previous surgery in the abdominal area.
- Any previous treatment in the abdominal area.
- Planning to receive treatment of any kind in the abdominal area.
- Acute inflammatory process and/or infection at the injection site.
- Treatment of skin area with dermatosis.
- Eczema, exanthema or open wounds.
- Previous application of over the counter or prescription, oral or topical, anti-wrinkle or skin enhancer products on the abdominal skin within the past 3 months unless allowed by the study and is continued throughout the study.
- Any contraindication to treatment with biostimulatory products based on the product's IFU.
- Previous pregnancy or intending to become pregnant during study participation.
- Known hypersensitivity to biostimulatory products or any of their formulation ingredients.
- Allergic reaction to topical and local anesthetics.
- Currently using anticoagulant therapy.
- Haemophilia / bleeding disorder.
- Chemotherapy, radiotherapy or high doses of corticosteroids.
- Systemic infection (e.g., hepatitis).
- Uncontrolled diabetes mellitus.
- Any medical condition that may put the participant at increased risk with exposure to biostimulatory products.
- Any medication that might modulate the immune response.
- Any other illness or condition that, in the opinion of the investigator, would mean that study participation was not in the best interest of the prospective participant.
- Is a female of childbearing potential and not using medically effective birth control or is pregnant or lactating.
- Any serious disease or disorder (medical or psychiatric) that could, in the opinion of the investigator, interfere with the safe completion of treatment according to this protocol or with study.
- Injection of local anesthesia into the flap during abdominoplasty surgery.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Arm 1
Subjects in Arm 1 will receive injections of biostimulatory products (Radiesse(+) undiluted, Radiesse diluted 1:1, Radiesse diluted 1:2, Sculptra, Ellanse, HArmonyCa) at 3 timepoints (six months, three months and two weeks) prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
|
Expérimental: Arm 2 - Radiesse Classic (1:1 Dilution)
Five participants in Arm 2 will receive Radiesse Classic diluted 1:1 with sterile saline (CaHA-CMC 1:1) and saline control injections at separate predefined abdominal injection sites. All injections will be administered at a single protocol-defined timepoint, 6 months prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
|
Expérimental: Arm 2 - Sculptra
Five participants in Arm 2 will receive Sculptra diluted with 5 mL of sterile saline and saline control injections at separate predefined abdominal injection sites. All injections will be administered at a single protocol-defined timepoint, 6 months prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Arm 1 - Ultrasound Analyses - Skin Thickness (mm)
Délai: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Ultrasound of injection site tissue analyses (dermal thickness (mm)) |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 1 - Ultrasound Analyses - Elastosis
Délai: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Elastosis assessed by ultrasound at the injection site and reported according to the study-defined ultrasound elastosis category/grade. |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 1 - Ultrasound Analyses - Microvascular Formation
Délai: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Microvascular formation assessed by ultrasound at the injection site and reported according to the study-defined category/grade. |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Skin Thickness (mm)
Délai: 6 months prior to surgery timepoint(s)
|
Ultrasound of injection site tissue analyses (dermal thickness (mm)) |
6 months prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Elastosis
Délai: 6 months prior to surgery timepoint(s)
|
Elastosis assessed by ultrasound at the injection site and reported according to the study-defined ultrasound elastosis category/grade |
6 months prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Microvascular Formation
Délai: 6 months prior to surgery timepoint(s)
|
Microvascular formation assessed by ultrasound at injection site and reported according to the study-defined category/grade. |
6 months prior to surgery timepoint(s)
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety Assessment
Délai: through study completion, an average of 6 months
|
Any patient- or investigator-observed adverse event |
through study completion, an average of 6 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Ann P Marx, MD, Merz North America, Inc.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Troubles induits chimiquement
- Effets secondaires et effets indésirables liés aux médicaments
- Extravasation de matériel diagnostique et thérapeutique
- Conditions pathologiques, signes et symptômes
- Réaction au site d'injection
- Thérapeutique
- Voies d'administration du médicament
- Pharmacothérapie
- Injections
Autres numéros d'identification d'étude
- M900311010
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
individual data will be summarized for analyses
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .